

Title (en)
USE OF SULFATED HYALURONIC ACID

Title (de)
VERWENDUNG SULFATIERTER HYALURONSÄURE

Title (fr)
UTILISATION D'ACIDE HYALURONIQUE SULFATE

Publication
EP 1737412 A2 20070103 (DE)

Application
EP 04790993 A 20041028

Priority
• EP 2004012225 W 20041028
• DE 10352137 A 20031104

Abstract (en)
[origin: WO2005046562A2] Disclosed is the use of sulfated hyaluronic acid for inhibiting or treating inflammatory states of the eye, especially blepharitis and conjunctivitis, among other things.

IPC 8 full level
A61K 31/728 (2006.01); **A61K 45/06** (2006.01); **A61P 27/02** (2006.01)

CPC (source: EP)
A61K 31/728 (2013.01); **A61K 45/06** (2013.01); **A61P 27/02** (2017.12)

Citation (search report)
See references of WO 2005046562A2

Citation (examination)
• DE 10053866 A1 20020508 - CONDOMI ERFURT PRODUKTIONS GMB [DE]
• WO 02069984 A2 20020912 - KNOELL HANS FORSCHUNG EV [DE], et al
• WO 9525751 A1 19950928 - FIDIA ADVANCED BIOPOLYMERS SRL [IT], et al
• DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1990 (1990-12-01), HE Z ET AL: "[The clinical use of sodium hyaluronate eyedrops as a substitute for tears].", Database accession no. NLM2101365 & YAN KE XUE BAO = EYE SCIENCE / "YAN KE XUE BAO" BIAN JI BU DEC 1990 LNKD- PUBMED:2101365, vol. 6, no. 3-4, December 1990 (1990-12-01), pages 111 - 112, ISSN: 1000-4432

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL HR LT LV MK

DOCDB simple family (publication)
WO 2005046562 A2 20050526; WO 2005046562 A3 20081211; DE 10352137 A1 20050616; EP 1737412 A2 20070103

DOCDB simple family (application)
EP 2004012225 W 20041028; DE 10352137 A 20031104; EP 04790993 A 20041028